In-House Biomarker Testing Shortens Time to Treatment Decision for mNSCLC

This retrospective analysis compared molecular testing outcomes among newly diagnosed cases of metastatic non–small cell lung cancer (mNSCLC) from 2 periods: March 2017 to May 2019 and July 2019 to March 2021.

Related Keywords

Sunnybrook ,Alberta ,Canada ,Toronto ,Ontario , ,Sunnybrook Health Sciences Centre ,From March ,Mnsclc ,Metastatic Non Small Cell Lung Cancer ,In House Testing ,Time To Treatment Decision ,